more

Nabriva Therapeutics AG (NBRV)

(Delayed Data from NSDQ)

$2.16 USD

+0.01 (0.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.16 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 29,2020

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

biotechs

Nabriva Soars on Agreement With Merck to Distribute Sivextro

by Zacks Equity Research Published on July 16,2020

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

biotechs

Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%

by Zacks Equity Research Published on June 10,2020

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

Nabriva's Shares March Higher, Can It Continue?

by Zacks Equity Research Published on June 08,2020

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

NBRVPositive Net Change

medical

Implied Volatility Surging for Nabriva (NBRV) Stock Options

by Zacks Equity Research Published on June 01,2020

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

NBRVPositive Net Change

biotechs

Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)

by Zacks Equity Research Published on May 07,2020

Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NBRVPositive Net Change

Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 06,2020

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.

biotechs

Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick

by Zacks Equity Research Published on April 14,2020

Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

NBRVPositive Net Change

medical

Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session

by Zacks Equity Research Published on April 02,2020

Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Idera Completes Recruitment in Late-Stage Melanoma Study

by Zacks Equity Research Published on March 06,2020

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

biotechs

AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates

by Zacks Equity Research Published on March 05,2020

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

biotechs

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research Published on March 03,2020

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

biotechs

Will Nabriva Therapeutics Continue to Surge Higher?

by Zacks Equity Research Published on January 22,2020

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

NBRVPositive Net Change

medical

Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

by Zacks Equity Research Published on August 21,2019

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

biotechs

Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta

by Zacks Equity Research Published on August 20,2019

The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

biotechs

Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

by Zacks Equity Research Published on August 19,2019

Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.

biotechs

Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock?

by Zacks Equity Research Published on August 14,2019

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

NBRVPositive Net Change

medical

Melinta (MLNT) Announces Preliminary Product Sales for Q2

by Zacks Equity Research Published on July 17,2019

Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.

pharmaceuticals

Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin

by Zacks Equity Research Published on June 26,2019

The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.